Hepatotoxicity and EGFR inhibition

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 3, 2008, Pages 200-201

  Ramanarayanan, Jeyanthi ^a   Krishnan, Ganapathy S ^b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE HEPATITIS; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; INHIBITION KINETICS; LIVER FUNCTION; LIVER TOXICITY; LUNG CANCER; MONOTHERAPY; PANCREAS CANCER; REVIEW; SIDE EFFECT; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PANCREAS TUMOR; TOXIC HEPATITIS;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HEPATITIS, TOXIC; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 42049110133     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin Adv Hematol Oncol. 2008;6:191-194,199-201.
2. Bonner JA, Harari PM, Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallingeret S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol. 2005;23(16S):1.
5. Hidalgo M, Sin LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
6. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer. 2004;6:S20-3.
7. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Sin LL. Multi-center phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
8. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787-4792.
9. Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med. 2006; 354:731-739.
10. Benichou C. Criteria for drug induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.
11. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485.
12. Wolff T, Strecker M. Endogenous and exogenous factors modifying the activity of human liver cytochrome P-450 enzymes. Exp Toxicol Pathol. 1992;44:263-271.
13. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Phamacol Toxicol. 1998;38:389-430.
14. Seli N, Uematsu K, Shibakuki R, et al. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol. 2006;24:3213-3214.
15. Carlini F, Papal do F, Fabi A, et al. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol. 2006;24(35):e60-1.
16. Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treaurientwith gefitinib. J Clin Oncol. 2005;23:8531-8533.
17. Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. JOP 2007;8:39-43.
18. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007;25:3055-3060.